ACU193 for Alzheimer's Disease (INTERCEPT-AD Trial)

"As of this moment, clinicaltrials.gov indicates that recruitment for the trial is ongoing. This medical study was initially publicized on June 21st 2021 and has been regularly updated since then, with its most recent amendment occurring October 28th 2022."

"This medical study demands 62 participants that match the qualifications for inclusion. Two of the sites offering this trial are Neuro-Behavioral Clinical Research, Inc. in North Canton, Ohio and Atlanta Center for Medical Research in Atlanta, Georgia."

"The research team is seeking out individuals aged between 55 and 90 who meet the criteria for this clinical trial."

"This experiment is admitting 62 individuals suffering from Alzheimer's between the ages of 55 and 90. To qualify, candidates must fulfill a multitude of criteria including having an MMSE score between 18 to 30 (inclusive), a CDR rating of 0.5 or 1.0, weigh at least 41kg (90lbs) but no more than 113 kg (250 lbs). Additionally, they need to be willing and able to comply with scheduled visits as well as consenting to APOE genotyping if female participants are not surgically sterile; they must also be post-menopausal for one year with elevated FSH levels or two years without"

"The primary outcome of this medical trial, which will be tracked from Baseline up to 20 weeks for SAD and 24 or 28 weeks for MADs is a change in clinical laboratory tests. Secondary objectives include estimating the area under the plasma concentration-time curve (AUC∞), volume at terminal phase (Vz) and time to reach peak blood levels (Tmax(obs))."

"Considering the limited data on ACU193's efficacy and safety, it was rated a 1."

"Neuro-Behavioral Clinical Research, Inc. in North Canton, Ohio, Atlanta Center for Medical Research in Atlanta, Georgia and Orange County Research Institute in Anaheim, California are 3 of the 19 medical sites running this trial."